Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants
- PMID: 8556519
- PMCID: PMC368388
- DOI: 10.1128/cdli.1.6.670-677.1994
Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants
Abstract
Respiratory syncytial virus (RSV) convalescent-phase sera and control sera from both infants ( < 6 months) and older individuals (1.5 to 90 years) were assayed for RSV-specific antibodies by neutralization, in vitro enhancing activity, and immunoprecipitation. Enhancement of RSV infection in U937 cells was demonstrated with convalescent-phase sera and was shown to be dependent on Fc receptors by blocking with human immunoglobulin G (P < 0.01). Convalescent-phase sera from infants enhanced infection at concentrations closer to physiological ones (10(-1) to 10(-3) dilutions of serum), while convalescent-phase sera from older individuals enhanced infection only at much lower concentrations (10(-3) to 10(-6) dilutions of serum; P < 0.01). To our knowledge, this is the first report of RSV-enhancing antibody activity in the sera of infants. The observed enhancing activity and the low neutralizing antibody levels are confined mostly to convalescent-phase sera from infants aged 0 to 6 months, suggesting that these factors may contribute to the increased severity of RSV disease frequently encountered in young infants.
Similar articles
-
In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.J Virol. 2017 Oct 13;91(21):e00851-17. doi: 10.1128/JVI.00851-17. Print 2017 Nov 1. J Virol. 2017. PMID: 28794038 Free PMC article.
-
Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort.J Med Virol. 2013 Nov;85(11):2020-5. doi: 10.1002/jmv.23696. J Med Virol. 2013. PMID: 23983183 Free PMC article.
-
Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.EBioMedicine. 2017 Feb;16:124-135. doi: 10.1016/j.ebiom.2017.01.014. Epub 2017 Jan 16. EBioMedicine. 2017. PMID: 28111238 Free PMC article.
-
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.Front Immunol. 2019 Mar 22;10:548. doi: 10.3389/fimmu.2019.00548. eCollection 2019. Front Immunol. 2019. PMID: 30967872 Free PMC article. Review.
-
Fc gamma receptors in respiratory syncytial virus infections: implications for innate immunity.Rev Med Virol. 2014 Jan;24(1):55-70. doi: 10.1002/rmv.1773. Epub 2013 Nov 14. Rev Med Virol. 2014. PMID: 24227634 Free PMC article. Review.
Cited by
-
A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.Trends Microbiol. 2016 Dec;24(12):933-943. doi: 10.1016/j.tim.2016.09.003. Epub 2016 Oct 14. Trends Microbiol. 2016. PMID: 27751627 Free PMC article. Review.
-
Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19.Heliyon. 2023 Jul 4;9(7):e17958. doi: 10.1016/j.heliyon.2023.e17958. eCollection 2023 Jul. Heliyon. 2023. PMID: 37483779 Free PMC article.
-
Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.J Virol. 1997 Jun;71(6):4226-32. doi: 10.1128/JVI.71.6.4226-4232.1997. J Virol. 1997. PMID: 9151809 Free PMC article.
-
Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.Mol Immunol. 2022 Dec;152:172-182. doi: 10.1016/j.molimm.2022.11.010. Epub 2022 Nov 10. Mol Immunol. 2022. PMID: 36371813 Free PMC article. Review.
-
Contribution of Fcγ Receptor-Mediated Immunity to the Pathogenesis Caused by the Human Respiratory Syncytial Virus.Front Cell Infect Microbiol. 2019 Mar 29;9:75. doi: 10.3389/fcimb.2019.00075. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 30984626 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical